Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001 · Completed

Last updated 2026-05-28

This clinical trial compared the effects of biphasic insulin aspart 70/30 and exenatide in adults with type 2 diabetes who were not meeting blood sugar targets while taking metformin and a sulfonylurea.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 373 people

Who can join Ages 18–80 · all sexes

Timeline Started 2006-04 · est. completion 2007-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00313001 ↗

Description as written by the study sponsor.

This trial is conducted in the United States of America (USA). The study will compare A1C reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily to patients receiving exenatide twice daily. Patients enrolled in the study will be insulin naive patients who have not achieved glycemic control with metformin and sulfonylurea.

Treatments tested

biphasic insulin aspart Drug
exenatide Drug

Main thing measured	Superiority as assessed by HbA1c reduction
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00313001 ↗